Clinical and biochemical impact of low-dose atorvastatin in psoriasis: a case-control study
DOI:
https://doi.org/10.59736/IJP.24.02.1029Keywords:
Atorvastatin, Dyslipidemia, PsoriasisAbstract
Background: Psoriasis is a chronic immune-mediated inflammatory disorder associated with metabolic abnormalities, including dyslipidemia. Statins may provide lipid-lowering as well as anti-inflammatory benefits. Our objective is to evaluate the clinical and biochemical effects of low-dose atorvastatin in patients with psoriasis.
Methods: This case-control study was conducted at Hayatabad Medical Complex and Khyber Girls Medical College, Peshawar, Pakistan, from February to September 2018. Sixty adults with psoriasis of at least one year duration and confirmed dyslipidemia were allocated into two groups. The intervention group received atorvastatin 10 mg daily plus standard psoriasis treatment for 12 weeks, while the control group received standard treatment alone. Psoriasis Area and Severity Index (PASI) score and fasting lipid profile were assessed at baseline and after 12 weeks.
Results: Thirty participants were included in each group. The intervention group showed significant improvement in PASI score and lipid profile after 12 weeks. Mean PASI score decreased from 2.06±0.61 to 1.26±0.45 (p<0.001). Significant reductions were observed in total cholesterol, triglycerides, LDL cholesterol, and VLDL cholesterol, with an increase in HDL cholesterol (p<0.001). No significant changes were observed in the control group.
Conclusion: Low-dose atorvastatin may improve psoriasis severity and dyslipidemia when used as adjunct therapy. Larger multicenter trials are recommended.
References
Egeberg A. Psoriasis and comorbidities. Dan Med J. 2016;63(2): B5187.
Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014; 32:227-255. doi:10.1146/annurev-immunol-032713-120225.
Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994. doi:10.1016/S0140-6736(14)61909-7.
Flammer AJ, Ruschitzka F. Psoriasis and atherosclerosis: two plaques, one syndrome? Eur Heart J. 2012;33(16):1989-91. doi:10.1093/eurheartj/ehs157.
Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality. Arch Dermatol. 2010;146(8):891-5. doi:10.1001/archdermatol.2010.186.
Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(5):518-25. doi:10.1001/jamadermatol.2013.1073.
Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases. J Am Acad Dermatol. 2017;76(3):377-90. doi: 10.1016/j.jaad.2016.07.064.
Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases. J Invest Dermatol. 2010;130(7):1785-96. doi:10.1038/jid.2010.103.
Samarasekera EJ, Neilson JM, Warren RB, et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013;168(4):805-12. doi:10.1111/bjd.12218.
Gisondi P, Fantin F, Del Giglio M, et al. Chronic plaque psoriasis and metabolic syndrome. Dermatology. 2011;223(1):14-20. doi:10.1159/000330392.
Published
Issue
Section
License
Copyright (c) 2026 Fazal Ur Rehman Bangash, Saima Nadeem, Anjum Ishaque, Naumana, Asawir Javed, Abida Yasmeen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
